PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

• FDA A greed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Co mplete their 30 – day F ollow-up • Recruitment Progressing as Planned with Approximately 6 80 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal